BPC 157 reversed liver fibrosis, normalized liver function, and either prevented or rapidly corrected portal hypertension in rats with bile duct-induced liver disease.
Portal hypertension reversedBPC 157 either prevented or rapidly reversed portal hypertension in rats with bile duct-induced liver fibrosis, depending on when treatment started
What the researchers found
BPC 157 reversed liver fibrosis and portal hypertension in rats with surgically ligated bile ducts — a well-established model of chronic liver disease. Treatment with BPC 157 (at both 10 μg/kg and 10 ng/kg doses) through multiple routes (drinking water, intraperitoneal injection, or local application) reduced jaundice, ascites, liver nodularity, bile duct dilation, and liver weight abnormalities. At the cellular level, BPC 157 counteracted necrosis, apoptosis, inflammation, hepatic stellate cell activation (the cells that drive fibrosis), and collagen deposition.
Liver function markers normalized (AST, ALT, GGT, ALP, bilirubin improved; albumin increased). Tissue oxidative stress markers (MDA) and nitric oxide levels returned to healthy ranges, with changes in NOS2 and NOS3 expression and reduced inflammatory cytokines (IL-6, TNF-α, IL-1β). Portal hypertension was either prevented entirely or rapidly reversed depending on when BPC 157 treatment began.
Why it matters
Liver fibrosis and portal hypertension are major causes of death in chronic liver disease, and current treatments are limited. BPC 157 showed remarkably comprehensive effects in this model — addressing fibrosis, inflammation, cell death, portal pressure, and liver function simultaneously. While this is an animal study, the breadth of effects across multiple outcome measures and the dose-response at very low concentrations make it a notable preclinical finding in the BPC 157 research literature.
The numbers in context
BPC 157: 10 μg/kg and 10 ng/kg · Multiple routes: oral, IP, local · Sacrifice at 2, 4, 6, 8 weeks · Normalized AST, ALT, GGT, ALP, bilirubin, albumin · Reduced IL-6, TNF-α, IL-1β · Reversed portal hypertension
How the study worked
Bile duct ligation (BDL) in rats to induce liver fibrosis and portal hypertension. BPC 157 was administered via three routes: continuously in drinking water, by intraperitoneal injection (starting 30 minutes post-surgery or at week 4), or by local bath application. Rats were sacrificed at 2, 4, 6, and 8 weeks. Outcomes included gross pathology, histology (necrosis, fibrosis, stellate cell activation via α-SMA, collagen via Mallory stain, proliferation via Ki-67), serum liver function tests, tissue oxidative stress and nitric oxide markers, NOS2/NOS3 Western blots, and inflammatory cytokine levels.
Who was studied
Male Wistar rats with bile duct ligation-induced liver fibrosis and portal hypertension
What this study cannot tell us
All results are from rats — no human liver fibrosis data exists for BPC 157. The bile duct ligation model causes obstructive liver disease, which differs from the most common human causes of fibrosis (alcohol, NAFLD, viral hepatitis). The study comes from the Sikiric group in Zagreb, which produces the vast majority of BPC 157 research — independent replication by other groups is limited. The breadth of claimed effects (fibrosis, necrosis, inflammation, portal hypertension, liver function, oxidative stress all reversed) is extraordinary for a single peptide and warrants independent validation.
How to read the evidence
This is a preclinical animal study from the primary BPC 157 research group in Zagreb. While the results are comprehensive across multiple endpoints, the lack of independent replication and exclusively animal data make this preliminary evidence.
When this study was published
Published in 2019. Part of the ongoing body of BPC 157 animal research from the Sikiric group. No human liver fibrosis trials have been published for BPC 157 as of the knowledge cutoff.
The bigger picture
Liver fibrosis affects hundreds of millions of people worldwide (from alcohol, obesity-related NAFLD, and viral hepatitis) and can progress to cirrhosis and death. There are very few drugs that can reverse established fibrosis. BPC 157's apparent ability to reverse fibrosis, reduce portal hypertension, and restore liver function across multiple outcome measures makes it one of the more intriguing preclinical candidates — but the field desperately needs independent replication and human trials to determine if these dramatic animal results translate to clinical medicine.
Questions still open
- Can any independent research group replicate these findings outside of the Zagreb group that produces most BPC 157 research?
- Would BPC 157 show similar effects in NAFLD/NASH-induced fibrosis models, which are more relevant to the global liver disease burden?
- What is the mechanism by which a single 15-amino-acid peptide appears to affect so many different pathological pathways simultaneously?
Common questions
Can BPC 157 treat liver disease in humans?
Why is portal hypertension so dangerous?
Read the original research
Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation.
European journal of pharmacology, 847, 130-142
Citation
Sever, Anita Zenko; Sever, Marko; Vidovic, Tinka; Lojo, Nermin; Kolenc, Danijela; Vuletic, Lovorka Batelja; Drmic, Domagoj; Kokot, Antonio; Zoricic, Ivan; Coric, Marijana; Vlainic, Josipa; Poljak, Ljiljana; Seiwerth, Sven; Sikiric, Predrag. (2019). Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation.. European journal of pharmacology, 847, 130-142. https://doi.org/10.1016/j.ejphar.2019.01.030